UCB SA (OTCMKTS:UCBJF) Given Consensus Rating of "Buy" by Brokerages

Key Points

• UCB SA (OTCMKTS:UCBJF) has a consensus “Buy” rating from six covering analysts, with firms including Stephens, Barclays, Deutsche Bank, Wolfe Research and Goldman Sachs issuing overweight/buy/outperform recommendations.
• Shares opened at $292.69 and have traded in the past year between $150.70 and $345.39, with a 50‑day SMA of $311.87 and 200‑day SMA of $287.35; the company reports a current ratio of 1.19, quick ratio 0.78 and debt‑to‑equity of 0.33.
• UCB is a Belgium‑based biopharmaceutical company focused on immunology and neurology, developing specialty medicines across small molecules and biologics.

UCB SA (OTCMKTS:UCBJF - Get Free Report) has received a consensus rating of "Buy" from the six analysts that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating.

A number of research firms have weighed in on UCBJF. Stephens restated an "overweight" rating on shares of UCB in a research report on Thursday, January 15th. Barclays reiterated an "overweight" rating on shares of UCB in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of UCB in a report on Monday, December 8th. Wolfe Research started coverage on UCB in a research report on Monday, February 23rd. They issued an "outperform" rating for the company. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of UCB in a research note on Monday, February 16th.

UCB Price Performance

Shares of UCB stock opened at $292.69 on Friday. UCB has a 1 year low of $150.70 and a 1 year high of $345.39. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company has a 50 day simple moving average of $311.87 and a two-hundred day simple moving average of $287.35.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB's work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.